40 related articles for article (PubMed ID: 15318840)
1. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
3. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Gerber GS; Contreras BA; Rukstalis DB
Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiology of lower urinary tract symptoms and use of doxazosin in the treatment of early stages of benign prostate hyperplasia].
Nurullaev RB
Lik Sprava; 2004; (3-4):101-3. PubMed ID: 15318840
[TBL] [Abstract][Full Text] [Related]
7. Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia.
Goldsmith DR; Plosker GL
Drugs; 2005; 65(14):2037-47. PubMed ID: 16162024
[TBL] [Abstract][Full Text] [Related]
8. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
9. [The objective of medical treatment: relieve the symptoms or stop the course?].
Desgrandchamps F
Ann Urol (Paris); 2006 Mar; 40 Spec No 1():14-6. PubMed ID: 16649585
[No Abstract] [Full Text] [Related]
10. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia.
Pool JL
Br J Clin Pract; 1996; 50(3):154-63. PubMed ID: 8733335
[TBL] [Abstract][Full Text] [Related]
12. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
